Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Parvin F. Peddi"'
Autor:
Parvin F. Peddi, Merry Tetef, Paul Coluzzi, Karo K. Arzoo, Eddie H. Hu, Maurice J. Berkowitz, David Chan, Dennis Moore, Brad Adams, Xiaoyan Wang, Sara A. Hurvitz
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Stomatitis is a frequent dose limiting toxicity of everolimus, an approved therapy for patients with metastatic breast cancer. No randomized trials of a prophylactic measure to prevent mucositis have been reported. Methods: We conducted a
Externí odkaz:
https://doaj.org/article/75c6ea8cccd543f2944ff91e58816f0f
Autor:
Parvin F. Peddi, Sara A. Hurvitz
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 6 (2014)
In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla®) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on r
Externí odkaz:
https://doaj.org/article/22ac18e7a89d4d729001531a9f00b68f
Publikováno v:
International Journal of Breast Cancer, Vol 2012 (2012)
Triple negative breast cancer is an aggressive form of breast cancer with limited treatment options and is without proven targeted therapy. Understanding the molecular basis of triple negative breast cancer is crucial for effective new drug developme
Externí odkaz:
https://doaj.org/article/629398dec0a64a8d80b0e7e027b6223f
Autor:
Sarah F. DAmbruoso, Alexandra Drakaki, Kauser Ahmed, Jennie Kung, Lee S. Rosen, Sara A. Hurvitz, Christopher Pietras, Peter Phung, Deborah J.L. Wong, Sidharth Anand, Daniel Karlin, Parvin F. Peddi, Wendy Simon, Jonathan W. Goldman, Neil S. Wenger, Anne Walling, John A. Glaspy, Katherine Santos, Anne Coscarelli
Publikováno v:
JCO Oncology Practice. 18:e484-e494
PURPOSE: Guidelines support early integration of palliative care (PC) into standard oncology practice; however, little is known as to whether outcomes can be improved by modifying health care delivery in a real-world setting. METHODS: We report our 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602c79581a16838aa13c01f449feb80e
https://doi.org/10.1200/op.21.00046
https://doi.org/10.1200/op.21.00046
Autor:
Parvin F. Peddi, Peter A. Fasching, Duan Liu, Emmanuel Quinaux, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Julie M. Cunningham, Richard M. Weinshilboum, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martín, Valerie Bee, Xiaoyan Wang, Liewei Wang, Eric Yang, Dennis J. Slamon, Sara A. Hurvitz
Publikováno v:
Clinical Cancer Research. 28:1854-1862
Purpose:Cardiac toxicity is a serious potential complication of HER2-directed therapies and anthracyclines. HER2 codon 655 and SLC28A3 gene polymorphisms have been reported to be associated with cardiac toxicity from anti-HER2 and anthracycline thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5f07eaa215963303aa694fa04de9178
https://doi.org/10.1158/1078-0432.ccr-21-1762
https://doi.org/10.1158/1078-0432.ccr-21-1762
Autor:
Sara A. Hurvitz, Dennis J. Slamon, Eric Yang, Liewei Wang, Xiaoyan Wang, Valerie Bee, Miguel Martín, Wolfgang Eiermann, Tadeusz Pienkowski, Richard M. Weinshilboum, Julie M. Cunningham, Adam Brufsky, Carla Falkson, John Crown, Vicente Valero, Nicholas J. Robert, Emmanuel Quinaux, Duan Liu, Peter A. Fasching, Parvin F. Peddi
Purpose:Cardiac toxicity is a serious potential complication of HER2-directed therapies and anthracyclines. HER2 codon 655 and SLC28A3 gene polymorphisms have been reported to be associated with cardiac toxicity from anti-HER2 and anthracycline thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67a8a6ce8ba2ede33f9bbcf929fedc7b
https://doi.org/10.1158/1078-0432.c.6531201
https://doi.org/10.1158/1078-0432.c.6531201
Autor:
Sara A. Hurvitz, Dennis J. Slamon, Eric Yang, Liewei Wang, Xiaoyan Wang, Valerie Bee, Miguel Martín, Wolfgang Eiermann, Tadeusz Pienkowski, Richard M. Weinshilboum, Julie M. Cunningham, Adam Brufsky, Carla Falkson, John Crown, Vicente Valero, Nicholas J. Robert, Emmanuel Quinaux, Duan Liu, Peter A. Fasching, Parvin F. Peddi
Supplementary Data from Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfb41bd07ee7afebaaf7f3ee83b21001
https://doi.org/10.1158/1078-0432.22483668.v1
https://doi.org/10.1158/1078-0432.22483668.v1
Autor:
Parvin F. Peddi
Publikováno v:
Current opinion in obstetricsgynecology. 34(1)
Triple negative breast cancer is the most aggressive subtype of breast cancer and has traditionally lacked targeted therapies leading to worse prognosis in most patients.We will review new targeted therapies for triple negative breast cancer includin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f234aef199c654e5584568a4fcd0b56e
https://pubmed.ncbi.nlm.nih.gov/34967815
https://pubmed.ncbi.nlm.nih.gov/34967815
Autor:
Dennis J. Slamon, Parvin F. Peddi
Publikováno v:
Current opinion in obstetricsgynecology. 33(1)
Purpose of review The field of HER2-positive breast cancer has seen tremendous advances in the last 2 years with largest number of new drugs in decades. The present review aims to summarize the cutting-edge research of the past 2 years and future dir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32640611b463da04fcf518db84c43222
https://pubmed.ncbi.nlm.nih.gov/33369581
https://pubmed.ncbi.nlm.nih.gov/33369581
Autor:
Parvin F. Peddi
Publikováno v:
Current Opinion in Obstetrics & Gynecology. 30:51-54
Purpose of review Hormone receptor (HR) positive breast cancer represents the vast majority of breast cancer cases. Treatment for these patients has been 5 years of endocrine therapy in the localized setting and endocrine therapy alone in the metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5708d86e2f89dd4eacfed9ed94381bb2
https://doi.org/10.1097/gco.0000000000000424
https://doi.org/10.1097/gco.0000000000000424